Intervacc AB

2E9

Company Profile

  • Business description

    Intervacc AB is a Swedish animal health company that develops, manufactures and commercializes veterinary vaccines based on its proprietary recombinant fusion protein technology platform. Its product, Strangvac, is a vaccine against equine strangles and is marketed across multiple European countries. The company is also developing Piggivac for Streptococcus suis infections in pigs and operates through animal health, veterinary pharmaceuticals and diagnostic services. Geographically, the company generates its revenue from Europe through vaccine sales and distribution partnerships, while expansion targets North America, Australia and New Zealand.

  • Contact

    Vastertorpsvagen 135 B
    Hagersten
    StockholmS-129 44
    SWE

    T: +46 812010600

    https://www.intervacc.se

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    16

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,927.75152.99-1.89%
DAX 4024,802.78661.03-2.60%
Dow JONES (US)48,147.33949.73-1.93%
FTSE 10010,346.34106.34-1.02%
HKSE22,410.80430.82-1.89%
NASDAQ22,617.731,261.47-5.28%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5006,910.39265.44-3.70%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers